drugset / Trial / NCT03391193

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

NCT03391193

Phase 3 Completed 301 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of the study is to to assess the immunogenicity and safety of a quadrivalent influenza vaccine in a multi-dose presentation compared to a quadrivalent influenza vaccine in single-dose presentation, in children aged 6 months to 17 years.

Timeline

Start
2017-12-19
Primary completion
2018-03-28
Completion
2018-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Multi-dose Quadrivalent Influenza Vaccine Vaccine 0.5 ml Intramuscular
Comparator NITRAMINE Vaccine 0.5 ml Intramuscular

Indications